Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 6,687 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total value of $80,244.00. Following the sale, the chief executive officer now directly owns 5,501,715 shares of the company’s stock, valued at approximately $66,020,580. This trade represents a 0.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Alphatec Price Performance

Shares of ATEC opened at $11.67 on Friday. The company has a market cap of $1.65 billion, a P/E ratio of -9.12 and a beta of 1.41. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm’s 50 day moving average price is $9.80 and its 200 day moving average price is $8.08.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Barclays raised their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday. Needham & Company LLC boosted their price target on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

Institutional Trading of Alphatec

A number of large investors have recently modified their holdings of ATEC. Point72 Asset Management L.P. boosted its holdings in Alphatec by 65.2% in the second quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company’s stock valued at $33,365,000 after purchasing an additional 1,260,137 shares during the period. State Street Corp raised its position in Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock valued at $17,453,000 after purchasing an additional 287,350 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Alphatec by 11.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after buying an additional 297,850 shares during the period. Fred Alger Management LLC grew its position in shares of Alphatec by 0.8% during the second quarter. Fred Alger Management LLC now owns 2,638,303 shares of the medical technology company’s stock worth $27,570,000 after buying an additional 21,078 shares in the last quarter. Finally, Royce & Associates LP increased its stake in shares of Alphatec by 15.9% during the third quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock worth $6,740,000 after buying an additional 165,954 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.